Skip to content

A Guided Imagery Tobacco Cessation Intervention Delivered by a Quit Line and Website

A Guided Imagery Tobacco Cessation Intervention Delivered by a Quit Line and Website

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02968381
Acronym
QLImagery
Enrollment
121
Registered
2016-11-18
Start date
2018-05-01
Completion date
2022-01-21
Last updated
2022-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Guided Imagery, Smoking Cessation, Smoking, Tobacco, Tobacco Smoking, Tobacco Use

Keywords

tobacco, smoking, imagery

Brief summary

Tobacco use is still the leading cause of preventable disease and death in the United States. Tobacco quit lines are effective at helping smokers to quit, but quit lines are underutilized, especially by men and racial/ethnic minorities. Guided imagery is effective at helping people quit smoking, and is appealing to males and diverse racial groups, but has limited reach. The proposed study will develop and test the feasibility and acceptability of a guided imagery tobacco cessation intervention that is delivered by a combination of quit line coaches and an interactive website. The investigators hypothesize that guided mental imagery delivered using the quit line coaching model combined with an interactive website could be an effective intervention strategy.

Detailed description

The objective of this three year R34 application is to develop and test the feasibility of a theory-driven, telephone plus web-based, guided mental imagery intervention for smoking cessation. Aim 1. Develop a theory-based, guided mental imagery tobacco cessation intervention for quit line callers with input from expert consultants in health disparities and a Community Advisory Board representing diverse populations and tobacco control stakeholders. The intervention will include phone-based coaching, an interactive website, and optional cessation medication. It will be focus tested with 40 smokers (from diverse racial/ethnic and age groups with at least 40% males), and usability tested with 5 smokers. Aim 2. Develop training and competency standards for, and train, four coaches in the implementation of the guided imagery and control interventions. Coaches will be assessed at 6-weeks and 6-months post-training for implementation fidelity and satisfaction. Aim 3. Conduct a feasibility trial (N=100) to gather preliminary data on the effects of the guided mental imagery intervention on quit line callers' tobacco use, cravings, and self-efficacy to quit smoking, and to refine study procedures, including recruitment, retention, and use of intervention components. Participants will be randomly assigned to receive either the Imagery Intervention (N=50) or an attention control condition (N=50) as delivered by study coaches. Participants will be assessed at baseline, 6-weeks and 6-months post-enrollment. Primary outcomes will be self-reported point prevalence and prolonged abstinence of tobacco use. Biochemical validation will be conducted on a sub-sample to determine validity of self-reported abstinence in this population. Secondary outcomes will be self-reported cravings and self-efficacy.

Interventions

Telephone coaching sessions, use of guided imagery and website.

BEHAVIORALControl Condition

Telephone coaching using standard cognitive behavioral methods

Sponsors

National Center for Complementary and Integrative Health (NCCIH)
CollaboratorNIH
West Virginia University
CollaboratorOTHER
University of Arizona
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Current smoker trying to quit * Speak English * Internet access * Email access * Live in the state of Arizona, USA

Exclusion criteria

* Having enrolled and participated in Quit line services in the past 12 months * Diagnosed with a serious mental illness (e.g. current depression)

Design outcomes

Primary

MeasureTime frameDescription
Number of Participants With Change in Self-reported 7-day Tobacco Abstinence From Baseline to Follow-up6 monthsTobacco use over the past seven days is assessed by project staff at 6-months post-enrollment. Tobacco use includes cigarettes, smokeless tobacco, and other types of tobacco. The question is asked Have you smoked, even a puff, in the last 7 days? Have you used any other form of tobacco in the last 7 days? If yes to either question, the participant is asked to indicate what type of tobacco was used and how much was used (e.g., how many cigarettes did you smoke on a typical day?).
Number of Participants With Change in Self-reported Tobacco 30-day Abstinence From Baseline to Follow-up6 monthsTobacco use over the past 30 days is assessed by project staff at 6-months post-enrollment. Tobacco use includes cigarettes, smokeless tobacco, and other types of tobacco. The question is asked Have you smoked, even a puff, in the last 30 days? Have you used any other form of tobacco in the last 30 days? If yes to either question, the participant is asked to indicate what type of tobacco was used and how much was used (e.g., how many cigarettes did you smoke on a typical day?).

Secondary

MeasureTime frameDescription
Change in Tobacco Use for Non-quitters From Baseline to Follow-up6 monthsAssessed by project staff at 6-months post-enrollment.
Change in Self-efficacy for Quitting From Baseline to Follow-up6 monthsAn abbreviated version of the Condiotte and Lichtenstein (1981) Confidence Questionnaire consisting of 5 items for quitters and 6 items for non-quitters. All items are scored using a 5-point Likert scale where 1 is low/less and 5 is high/more. We calculated an average score of the items (which would have a value between 1 and 5).
Change in Nicotine Cravings From Baseline to Follow-up6 monthsThis was assessed using 1 item adapted from the Shiffman (2004) Rating Scale (How much have you craved tobacco today?). Responses were coded using a 6-point Likert scale from not at all (code 0) to a great deal (code 5).

Countries

United States

Participant flow

Participants by arm

ArmCount
Imagery Intervention
Participants will receive imagery intervention which includes 6 telephone sessions, an introduction to guided imagery, setting a quit date, setting guided imagery schedule, and a description of and instructions for using the study website. Imagery Intervention: Telephone coaching sessions, use of guided imagery and website.
56
Control Condition
Participants will receive an attention control condition which includes 6 telephone sessions, an introduction to cognitive behavioral telephone coaching, setting a quit date, creating a quit plan, and a description of and instructions for using the Arizona Smokers' Help Line website. Control Condition: Telephone coaching using standard cognitive behavioral methods
49
Total105

Baseline characteristics

CharacteristicImagery InterventionControl ConditionTotal
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
0 Participants1 Participants1 Participants
Age, Categorical
Between 18 and 65 years
56 Participants48 Participants104 Participants
Age, Continuous48.5 years
STANDARD_DEVIATION 15.8
51.6 years
STANDARD_DEVIATION 14.5
50.5 years
STANDARD_DEVIATION 14.4
Ethnicity (NIH/OMB)
Hispanic or Latino
8 Participants9 Participants17 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
48 Participants40 Participants88 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Race (NIH/OMB)
American Indian or Alaska Native
2 Participants1 Participants3 Participants
Race (NIH/OMB)
Asian
1 Participants1 Participants2 Participants
Race (NIH/OMB)
Black or African American
2 Participants2 Participants4 Participants
Race (NIH/OMB)
More than one race
3 Participants3 Participants6 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants1 Participants1 Participants
Race (NIH/OMB)
Unknown or Not Reported
3 Participants2 Participants5 Participants
Race (NIH/OMB)
White
45 Participants39 Participants84 Participants
Region of Enrollment
United States
56 participants49 participants105 participants
Sex: Female, Male
Female
36 Participants33 Participants69 Participants
Sex: Female, Male
Male
20 Participants16 Participants36 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 560 / 49
other
Total, other adverse events
0 / 560 / 49
serious
Total, serious adverse events
0 / 560 / 49

Outcome results

Primary

Number of Participants With Change in Self-reported 7-day Tobacco Abstinence From Baseline to Follow-up

Tobacco use over the past seven days is assessed by project staff at 6-months post-enrollment. Tobacco use includes cigarettes, smokeless tobacco, and other types of tobacco. The question is asked Have you smoked, even a puff, in the last 7 days? Have you used any other form of tobacco in the last 7 days? If yes to either question, the participant is asked to indicate what type of tobacco was used and how much was used (e.g., how many cigarettes did you smoke on a typical day?).

Time frame: 6 months

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Imagery InterventionNumber of Participants With Change in Self-reported 7-day Tobacco Abstinence From Baseline to Follow-up15 Participants
Control ConditionNumber of Participants With Change in Self-reported 7-day Tobacco Abstinence From Baseline to Follow-up21 Participants
Primary

Number of Participants With Change in Self-reported Tobacco 30-day Abstinence From Baseline to Follow-up

Tobacco use over the past 30 days is assessed by project staff at 6-months post-enrollment. Tobacco use includes cigarettes, smokeless tobacco, and other types of tobacco. The question is asked Have you smoked, even a puff, in the last 30 days? Have you used any other form of tobacco in the last 30 days? If yes to either question, the participant is asked to indicate what type of tobacco was used and how much was used (e.g., how many cigarettes did you smoke on a typical day?).

Time frame: 6 months

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Imagery InterventionNumber of Participants With Change in Self-reported Tobacco 30-day Abstinence From Baseline to Follow-up12 Participants
Control ConditionNumber of Participants With Change in Self-reported Tobacco 30-day Abstinence From Baseline to Follow-up16 Participants
Secondary

Change in Nicotine Cravings From Baseline to Follow-up

This was assessed using 1 item adapted from the Shiffman (2004) Rating Scale (How much have you craved tobacco today?). Responses were coded using a 6-point Likert scale from not at all (code 0) to a great deal (code 5).

Time frame: 6 months

ArmMeasureValue (MEAN)Dispersion
Imagery InterventionChange in Nicotine Cravings From Baseline to Follow-up2.1 score on a scaleStandard Deviation 1.2
Control ConditionChange in Nicotine Cravings From Baseline to Follow-up2.2 score on a scaleStandard Deviation 1.7
Secondary

Change in Self-efficacy for Quitting From Baseline to Follow-up

An abbreviated version of the Condiotte and Lichtenstein (1981) Confidence Questionnaire consisting of 5 items for quitters and 6 items for non-quitters. All items are scored using a 5-point Likert scale where 1 is low/less and 5 is high/more. We calculated an average score of the items (which would have a value between 1 and 5).

Time frame: 6 months

ArmMeasureValue (MEAN)Dispersion
Imagery InterventionChange in Self-efficacy for Quitting From Baseline to Follow-up4.1 units on a scaleStandard Deviation 1.1
Control ConditionChange in Self-efficacy for Quitting From Baseline to Follow-up4.0 units on a scaleStandard Deviation 1.2
Secondary

Change in Tobacco Use for Non-quitters From Baseline to Follow-up

Assessed by project staff at 6-months post-enrollment.

Time frame: 6 months

ArmMeasureValue (MEAN)Dispersion
Imagery InterventionChange in Tobacco Use for Non-quitters From Baseline to Follow-up9.1 CigarettesStandard Deviation 6.1
Control ConditionChange in Tobacco Use for Non-quitters From Baseline to Follow-up11.2 CigarettesStandard Deviation 9

Source: ClinicalTrials.gov · Data processed: Feb 18, 2026